OCTP.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 13:39):

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines...

Stats
Today's Volume	23.05M
Average Volume	5.88M
Market Cap	3.65M
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.330
ATR14	£0.00400 (1.21%)

Oxford Cannabinoid Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oxford Cannabinoid Financials

Annual	2022
Revenue:	£0
Gross Profit:	£-38 808.00 (0.00 %)
EPS:	£-0.00620

Q2	2023
Revenue:	£0
Gross Profit:	£-1 172.00 (0.00 %)
EPS:	£-0.00210

Q4	2022
Revenue:	£0
Gross Profit:	£-1 156.16 (0.00 %)
EPS:	£-0.00230

Q1	2023
Revenue:	£0
Gross Profit:	£-578.08 (0.00 %)
EPS:	£-0.00120

Financial Reports:

No articles found.

Oxford Cannabinoid

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.